Small Bowel Amyloidosis
- 126 Downloads
Purpose of Review
The goal of this paper is to review the literature on small bowel amyloidosis. Our review focuses on the underlying etiology, histopathology, clinical features, endoscopic and radiologic findings, and the mainstay of management.
The latest research shows changing epidemiological trends of different types of amyloidosis. It also reveals a better understanding of its pathophysiology and shows improvement in treatment outcomes.
Amyloidosis is a group of diseases of multiple etiologies and clinical presentations. It is characterized by pathological deposition of insoluble fibrillar proteins within various organs leading to disruption of their structure and function. The classification of amyloidosis includes primary, secondary, dialysis-related, senile, and hereditary. Amyloidosis can be systemic or localized. The incidence of AA amyloidosis is declining in frequency. If the gastrointestinal (GI) tract is involved, the small intestine is the most commonly affected site. Overall, outcomes among patients with newly diagnosed amyloidosis have improved. This article focuses on small bowel amyloidosis.
KeywordsSmall bowel Amyloidosis Gastrointestinal
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 4.• Cowan AJ, Skinner M, Seldin DC, Berk JL, Lichtenstein DR, O'Hara CJ, et al. Amyloidosis of the gastrointestinal tract: a 13-year, single-center, referral experience. Haematologica. 2013;98(1):141–6. https://doi.org/10.3324/haematol.2012.068155. This retrospective study details the clinical characteristics, treatment regimens, and survival rates of amyloidosis involving the gastrointestinal tract. CrossRefPubMedCentralPubMedGoogle Scholar
- 5.• Freudenthaler S, Hegenbart U, Schonland S, Behrens HM, Kruger S, Rocken C. Amyloid in biopsies of the gastrointestinal tract—a retrospective observational study on 542 patients. Virchows Arch. 2016;468(5):569–77. This study is the largest series investigating the histopathological and demographic characteristics of amyloidosis in gastrointestinal biopsies. https://doi.org/10.1007/s00428-016-1916-y.CrossRefPubMedCentralPubMedGoogle Scholar
- 6.• Lane T, Pinney JH, Gilbertson JA, Hutt DF, Rowczenio DM, Mahmood S, et al. Changing epidemiology of AA amyloidosis: clinical observations over 25 years at a single national referral centre. Amyloid. 2017;24(3):162–6. This large single center retrospective study investigates the changing epidemiology of patients diagnosed with AA amyloidosis over a 25-year period. https://doi.org/10.1080/13506129.2017.1342235.CrossRefPubMedGoogle Scholar
- 7.• Tosca Cuquerella J, Bosca-Watts MM, Anton Ausejo R, Tejedor Alonso S, Mora De Miguel F, Minguez Perez M. Amyloidosis in inflammatory bowel disease: a systematic review of epidemiology, clinical features, and treatment. J Crohns Colitis. 2016;10(10):1245–53. https://doi.org/10.1093/ecco-jcc/jjw080. This is an observational study and a systematic review of the prevalence of amyloidosis in IBD patients. CrossRefPubMedGoogle Scholar
- 10.• Greenstein AJ, Sachar DB, Panday AK, Dikman SH, Meyers S, Heimann T, et al. Amyloidosis and inflammatory bowel disease. A 50-year experience with 25 patients. Medicine (Baltimore). 1992;71(5):261–70. This landmark single center study is the largest case series of patients with secondary amyloidosis from underlying inflammatory bowel disease. https://doi.org/10.1097/00005792-199209000-00001.CrossRefGoogle Scholar
- 12.• Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007;356(23):2361–71. This is a comprehensive single center study on the long-term course of 374 patients with AA amyloidosis. https://doi.org/10.1056/NEJMoa070265.CrossRefPubMedGoogle Scholar
- 15.• Katoh N, Matsuda M, Ikeda S. Clinical, endoscopic, and histopathological features of localized immunoglobulin light chain (AL) amyloidosis in the gastrointestinal tract. Amyloid. 2015;22(4):254–6. https://doi.org/10.3109/13506129.2015.1075972. This study focuses on the endoscopic and histological findings in patients with localized AL amyloidosis of the gastrointestinal tract. CrossRefPubMedGoogle Scholar
- 16.• Mahmood S, Bridoux F, Venner CP, Sachchithanantham S, Gilbertson JA, Rowczenio D, et al. Natural history and outcomes in localized immunoglobulin light-chain amyloidosis: a long-term observational study. Lancet Haematol. 2015;2(6):e241–50. https://doi.org/10.1016/S2352-3026(15)00068-X. This large retrospective study reports the clinical features and long-term outcomes in patients with localized amyloidosis affecting the gastrointestinal tract. CrossRefPubMedGoogle Scholar
- 17.Tada S, Iida M, Yao T, Kawakubo K, Yao T, Okada M, et al. Endoscopic features in amyloidosis of the small intestine: clinical and morphologic differences between chemical types of amyloid protein. Gastrointest Endosc. 1994;40(1):45–50. https://doi.org/10.1016/S0016-5107(94)70008-7.CrossRefPubMedGoogle Scholar
- 18.• Iida T, Yamano H, Nakase H Systemic amyloidosis with gastrointestinal involvement: diagnosis from endoscopic and histological views. J Gastroenterol Hepatol 2017. https://doi.org/10.1111/jgh.13996. This recent literature review concentrates on the endoscopic and histological findings in patients with systemic amyloidosis with GI involvement.
- 20.Yoshimatsu S, Ando Y, Terazaki H, Sakashita N, Tada S, Yamashita T, et al. Endoscopic and pathological manifestations of the gastrointestinal tract in familial amyloidotic polyneuropathy type I (Met30). J Intern Med. 1998;243(1):65–72. https://doi.org/10.1046/j.1365-2796.1998.00247.x.CrossRefPubMedGoogle Scholar
- 22.• Alcalde-Vargas A, Leo-Carnerero E, Rojas-Mercedes N, Trigo-Salado C, Herrera-Justiniano JM, Márquez-Galán JL. Correlation between location of amyloid deposits and endoscopic and clinical manifestations in symptomatic gastrointestinal amyloidosis. Rev Esp Enferm Dig. 2015;107(1):49–51. This retrospective study correlates the location of amyloid deposits and its endoscopic appearance. PubMedGoogle Scholar
- 26.Lim AY, Lee JH, Jung KS, Gwag HB, Kim DH, Kim SJ, et al. Clinical features and outcomes of systemic amyloidosis with gastrointestinal involvement: a single-center experience. Korean J Intern Med. 2015;30(4):496–505. https://doi.org/10.3904/kjim.2015.30.4.496.CrossRefPubMedCentralPubMedGoogle Scholar
- 30.Siau K, Elzubeir A, Cooper SC, Iqbal T. Amyloidosis: an unusual cause of upper gastrointestinal bleeding. BMJ Case Rep 2016. https://doi.org/10.1136/bcr-2016-217653.
- 34.Groisman G, Cohen HI. Small intestinal amyloidosis: a rare cause of diverticular disease. Case Reports in Pathol. 2014;2014:1–4.Google Scholar
- 35.Tian L, Tang A, Zhang X, Mei Z, Liu F, Li J, et al. Incomplete ileus and hemafecia as the presenting features of multi-organ involved primary systemic AL amyloidosis: a rare case report. BMC Gastroenterol. 2017;17(1):72. https://doi.org/10.1186/s12876-017-0628-3.CrossRefPubMedCentralPubMedGoogle Scholar
- 46.• Sanchorawala V, Sun F, Quillen K, Sloan JM, Berk JL, Seldin DC. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience. Blood. 2015;126(20):2345–7. https://doi.org/10.1182/blood-2015-08-662726. This study looks at remission, durability, and long-term results in AL amyloidosis patients treated with HDM/SCT. CrossRefPubMedGoogle Scholar
- 47.• Muchtar E, Gertz MA, Kumar SK, Lacy MQ, Dingli D, Buadi FK, et al. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood. 2017;129(15):2111–9. https://doi.org/10.1182/blood-2016-11-751628. This study is a large single center retrospective analysis outlining trends in patient management and patient outcomes in patients newly diagnosed AL amyloidosis. CrossRefPubMedGoogle Scholar
- 48.• Okuda Y, Ohnishi M, Matoba K, Jouyama K, Yamada A, Sawada N, et al. Comparison of the clinical utility of tocilizumab and anti-TNF therapy in AA amyloidosis complicating rheumatic diseases. Mod Rheumatol. 2014;24(1):137–43. https://doi.org/10.3109/14397595.2013.854048. This study is a retrospective comparative study in patients with secondary amyloidosis due to rheumatic diseases receiving anti cytokine therapy. CrossRefPubMedGoogle Scholar
- 50.• Esatoglu SN, Hatemi G, Ugurlu S, Gokturk A, Tascilar K, Ozdogan H. Long-term follow-up of secondary amyloidosis patients treated with tumor necrosis factor inhibitor therapy: a STROBE-compliant observational study. Medicine (Baltimore). 2017;96(34):e7859. https://doi.org/10.1097/MD.0000000000007859. This is a single center long-term observational study reporting efficacy, safety, and outcomes of anti-TNF therapy in patients with secondary amyloidosis diverse underlying etiologies. CrossRefGoogle Scholar
- 52.• Banerjee D, Roeker LE, Grogan M, Swiecicki P, Poterucha J, Heimbach J, et al. Outcomes of patients with familial transthyretin amyloidosis after liver transplantation. Prog Transplant. 2017;27(3):246–50. https://doi.org/10.1177/1526924817715463. This study looks at transplant outcomes in patients with familial transthyretin amyloidosis. CrossRefPubMedGoogle Scholar
- 53.Reddy AB, Wright RA, Wheeler GE, Nazer H. Nonobstructive gastroparesis in amyloidosis improved with metoclopramide. Arch Intern Med. 1983;143(2):247–8. https://doi.org/10.1001/archinte.1983.00350020069014.CrossRefPubMedGoogle Scholar
- 54.Gil R, Debiais F, Lefevre JP, Pouget-Abadie JF, Marechaud R, Simmat G. Boissonnot amyloidosis with gastroparesis. Improvement with domperidone. Presse Médicale Presse Med. 1984;13(9):564.Google Scholar
- 55.Fushimi T, Takahashi Y, Kashima Y, Fukushima K, Ishii W, Kaneko K, et al. Severe protein losing enteropathy with intractable diarrhea due to systemic AA amyloidosis, successfully treated with corticosteroid and octreotide. Amyloid. 2005;12(1):48–53. https://doi.org/10.1080/13506120500032725.CrossRefPubMedGoogle Scholar